A Comparison of Remifentanil and Fentanyl in Patients Undergoing Surgery for Intracranial Mass Lesions

Abstract

Patients given remifentanil-based anesthesia for craniotomy had faster recovery times from anesthesia than did those given fentanyl-based anesthesia.

Postoperative condition after the use of remifentanil with a small dose of piritramide compared with a fentanyl-based protocol in patients undergoing craniotomy

“…This can possibly be explained by the piritramide used or the fact that both of our study groups received the same partial pressures of isoflurane in nitrous oxide. The MAC of isoflurane combined with remifentanil is believed to be lower compared to the combination of isoflurane and fentanyl [5,9]. Our findings, however, are in accordance with the findings of Sneyd and colleagues [10], who used remifentanil combined with propofol and nitrous oxide.…”

“…Talke and colleagues [8] proved this to be independent of the use of isoflurane. Both Balakrishnan and colleagues [9], and Guy and colleagues [6] reported mean times to extubation of 5 min after remifentanil using comparable protocols whereas we found 10 min in our study. This can possibly be explained by the piritramide used or the fact that both of our study groups received the same partial pressures of isoflurane in nitrous oxide.…”

Dexmedetomidine as an anesthetic adjuvant for intracranial procedures: Meta-analysis of randomized controlled trials

“…Remifentanil is an ultrashort-acting opioid and a suitable agent for use in neuroanesthesia [31][32][33][34]. However, only two trials focusing on perioperative hemodynamics and recovery profiles were included, and the analyses were influenced by heterogeneities.…”

Effects of fentanyl on emergence characteristics from anesthesia in adult cervical spine surgery: a comparison of fentanyl-based and sevoflurane-based anesthesia

“…Remifentanil and an α 2 -agonist (e.g., dexmedetomidine) would be expected to produce a more ideal profile for the emergence period of anesthesia with their reported attractive characteristics [16][17][18]. However, remifentanil is not yet commercially available and dexmedetomidine is not approved for intraoperative use in Japan.…”